Carbidopa/oxitriptan: Difference between revisions
CSV import |
CSV import |
||
| Line 36: | Line 36: | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
== Carbidopa/oxitriptan == | |||
<gallery> | |||
File:Carbidopa.svg|Carbidopa | |||
File:5-Hydroxy-L-Tryptophan (5-HTP).svg|5-Hydroxy-L-Tryptophan (5-HTP) | |||
</gallery> | |||
Latest revision as of 00:52, 20 February 2025
Carbidopa/oxitriptan is a combination medication used in the treatment of Parkinson's disease. It is a combination of two active ingredients: carbidopa and oxitriptan.
Pharmacology[edit]
Carbidopa is a peripheral decarboxylase inhibitor (PDI) that works by preventing the conversion of levodopa to dopamine outside the brain. This allows more levodopa to reach the brain, where it can be converted to dopamine, thus increasing the effectiveness of levodopa treatment.
Oxitriptan, also known as 5-hydroxytryptophan (5-HTP), is a naturally occurring amino acid and a chemical precursor in the biosynthesis of the neurotransmitters serotonin and melatonin from tryptophan. It is used as a dietary supplement, medication, and nutrient.
Clinical Use[edit]
Carbidopa/oxitriptan is used in the treatment of Parkinson's disease and Parkinson's disease dementia. It is also used in the treatment of dystonia, a neurological movement disorder.
Side Effects[edit]
Common side effects of carbidopa/oxitriptan include nausea, vomiting, loss of appetite, and feeling of tiredness. Serious side effects may include hallucinations, irregular heartbeat, and mood changes.
Contraindications[edit]
Carbidopa/oxitriptan should not be used in patients with a history of melanoma or with undiagnosed skin lesions, due to the potential risk of stimulating melanoma growth. It is also contraindicated in patients with a history of psychotic disorders due to the risk of exacerbating these conditions.
See Also[edit]
References[edit]
External Links[edit]
Carbidopa/oxitriptan[edit]
-
Carbidopa
-
5-Hydroxy-L-Tryptophan (5-HTP)
